Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: LUPRON DEPOT

« Back to Dashboard
Lupron Depot is a drug marketed by Abbvie Endocrine Inc and is included in five NDAs. It is available from one supplier. There are four patents protecting this drug.

This drug has one hundred patent family members in thirty-nine countries.

The generic ingredient in LUPRON DEPOT is leuprolide acetate. There are eighteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.

Summary for Tradename: LUPRON DEPOT

Patents:4
Applicants:1
NDAs:5
Suppliers: see list1

Clinical Trials for: LUPRON DEPOT

Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)
Status: Active, not recruiting Condition: Endometriosis; Dysmenorrhea; Dyspareunia

Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty
Status: Completed Condition: Precocious; Leuprolide Acetate; Luteinizing Hormone (LH); Gonadotrophin-releasing Hormone Agonist (GnRHa); Tanner Staging; Depot Formulation; Suppression of LH; Central Precocious Puberty (CPP); Gonadotrophin-releasing Hormone (GnRH); Lupron; GnRH Analog; Pediatrics Central Precocious Puberty

A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty
Status: Completed Condition: Puberty, Precocious

A Study of Leuprolide to Treat Prostate Cancer
Status: Completed Condition: Prostate Cancer

Melanoma Vaccine With Peptides and Leuprolide
Status: Completed Condition: Melanoma

Study of Lupron Depot In The Treatment of Central Precocious Puberty
Status: Completed Condition: Puberty, Precocious

Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer
Status: Recruiting Condition: Prostate Cancer

Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
Status: Active, not recruiting Condition: Fibrolamellar Carcinoma; Fibrolamellar Liver Cancer

Pharmacodynamics of Lorelin Depot (Leuprorelin Acetate - Bergamo) Compared to Lupron Depot ® (Leuprorelin Acetate - Abbot)
Status: Completed Condition: Healthy

Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
Status: Active, not recruiting Condition: Prostate Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Endocrine Inc
LUPRON DEPOT
leuprolide acetate
INJECTABLE;INJECTION020011-001Oct 22, 1990DISCNNo<disabled><disabled>
Abbvie Endocrine Inc
LUPRON DEPOT-PED
leuprolide acetate
INJECTABLE;INJECTION020263-007Aug 15, 2011RXYes<disabled><disabled>
Abbvie Endocrine Inc
LUPRON DEPOT
leuprolide acetate
INJECTABLE;INJECTION020517-003Jun 17, 2011RXNo8,921,326<disabled>Y<disabled>
Abbvie Endocrine Inc
LUPRON DEPOT
leuprolide acetate
INJECTABLE;INJECTION020708-001Mar 7, 1997RXYes6,036,976<disabled><disabled>
Abbvie Endocrine Inc
LUPRON DEPOT-PED
leuprolide acetate
INJECTABLE;INJECTION020263-004Apr 16, 1993DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: LUPRON DEPOT

Country Document Number Publication Date
Costa Rica11283May 31, 2010
China1292796Jan 03, 2007
Hungary0400378Dec 28, 2004
Poland204903Feb 26, 2010
Germany60211464Jun 22, 2006
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc